linjc16/ctgov huggingface dataset:
Ice-pick Intubation With Video Laryngoscopes in a Manikin With Restricted Access to the Airway

Study Overview
=================
Brief Summary
-----------------
To determine whether video laryngioscopes facilitate intubation in ice-pick position in a manikin with restricted access to the airway

Detailed Description
-----------------
To determine whether video laryngioscopes facilitate intubation in ice-pick position (also called inverse intubation) in a manikin with restricted access to the airway

Official Title
-----------------
Comparison of Different Video Laryngoscopes in Ice-pick Position in an Manikin With Restricted Access to the Airway

Conditions
-----------------
Tracheal Intubation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: anaesthesiologists experienced in airway management experienced in emergency medicine Exclusion Criteria: no experience in airway management missing infiormed consent

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Macintosh #3 Laryngoscope<br> | |
| Glidescope<br> | |
| Ambu Pentax AWS<br> | |
| McGrath<br> | |
| Airtraq<br> | |
| Storz C-MAC<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| tracheal intubation |  | max 5 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intubation, video laryngoscopes
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, prospective, single-arm study to assess safety and efficacy of Ruxolitinib in myelofibrosis (MF) based on a new prognostic stratification.

Official Title
-----------------
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis: a Multicenter, Prospective, Single-arm Clinical Study

Conditions
-----------------
Myelofibrosis

Intervention / Treatment
-----------------
* Drug: Ruxolitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients aged ≥18 years with a diagnosis of primary or secondary MF by World Health Organization and International Working Group for Myeloproliferative Neoplasms Research and Treat- ment (IWG-MRT) criteria; Received ruxolitinib treatment for ≥3 months. Exclusion Criteria: Malignant tumors with other progression or myelofibrosis secondary to other diseases; Exclude myelofibrosis patients after splenectomy; Patients with poor compliance with case follow-up or lost to follow-up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ruxolitinib<br> | Drug: Ruxolitinib<br>* Dosage based on platelet count<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of patients with a ≥35% reduction in palpable spleen volume from baseline. | Reduction in spleen volume is measured by magnetic resonance imaging/computerized tomography (MRI/CT). | From Week 0 through Week 24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of patients with ≥50% reduction in Total Symptom Score (TSS) from baseline. | TSS is assessed by the MPN-10. | From Week 0 through Week 24 |
Effectiveness of a Well-being Web-based Intervention

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the intervention Daily Challenge (MeYou Health, LLC), a behavioral intervention delivered online, is effective in improving individuals' well-being.

Official Title
-----------------
A Randomized Controlled Trial of the Effectiveness of the Web-based Well-being Intervention Daily Challenge

Conditions
-----------------
Focus of Study: Healthy Individuals

Intervention / Treatment
-----------------
* Behavioral: Daily Challenge


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults (18 years of age or older, 19 years of age or older if participant resides in Alabama or Nebraska) Provided informed consent to participate in the study Exclusion Criteria: Does not live in the United States of America Has a Facebook friend enrolled in the study Fails to complete the informed consent and registration process in the allotted time (45 minutes) Gender (recruitment will be titrated to ensure a minimum of 30% male ratio)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>Intervention: Daily Challenge | Behavioral: Daily Challenge<br>* Web-based behavioral intervention aiming to improve individuals' well-being.<br>|
| No Intervention: Control<br>Weekly Well-being, an email-based health information delivery service. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Well-being score, as determined by the Healthways Well-Being Assessment | Change in well-being score | Baseline, 30 days, 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interpersonal support score, as evaluated with the Interpersonal Support Evaluation List (ISEL) | Change in interpersonal support score. | Baseline, 30 days, 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
well-being, web-based intervention, social networks
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)

Study Overview
=================
Brief Summary
-----------------
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)

Official Title
-----------------
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive

Intervention / Treatment
-----------------
* Drug: cilomilast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Diagnosis of COPD and a history of cigarette smoking. Exclusion criteria: Significant heart or lung disease not associated with COPD. Significant stomach or intestinal disease.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: cilomilast<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measure of lung function and quality of life in patients with COPD |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| exacerbations in patients with COPD |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
smokers cough
Falls Of Unknown Origin (FUKNO) - Are Morbidity and Mortality Predictable in Patients Presenting With Falls?

Study Overview
=================
Brief Summary
-----------------
It is the investigators goal to identify the prevalence of underlying diseases, make disposition more rational, and establish risk stratification tools in elderly patients presenting with falls. Additionally, the outcome of standard care (clinical assessment only for disposition) will be compared with a new approach combining the standard of care with biomarker assisted disposition of elderly patients presenting with falls. Therefore the investigators are looking at the following points. Emergency department work-up Prevalence of underlying disease Developing algorithms for initial assessment Disposition a. Establishing biomarker enhanced disposition planning by using risk-stratification tools b. Comparing geriatric emergency assessment to standardized disposition planning

Official Title
-----------------
Falls Of Unknown Origin (FUKNO) - Are Morbidity and Mortality Predictable in Patients Presenting With Falls?

Conditions
-----------------
Accidental Falls, Underlying Disease of Falls

Intervention / Treatment
-----------------
* Other: Patients History


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All fall patients aged 65 years and older who presented to the emergency department giving written informed consent Exclusion Criteria: Patients below 65 years Non-fall patients above 65 years or lack of informed consent by patients or proxies

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| EFAB 65<br>Patients presenting to the emergency department with falls, above 65 years of age. Patients History will be taken as well as a blood sample | Other: Patients History<br>* History taking and drawing of a blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Data Collection via Case Report Form | 30 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute Morbidity | Data Collection via Case Report Form | 30 Days | 
| Institutionalisation | Data Collection via interview with general practitioner | 180 Days | 
| Disposition | Data collection via case report form | 30 Days | 
| Mortality | Data Collection via Case Report Form | 90 Days | 
| Mortality | Data Collection via Case Report Form | 180 Days | 
| Mortality | Data Collection via Case Report Form | 365 Days |
Predictive Factors of Long Term Outcome in MMN

Study Overview
=================
Brief Summary
-----------------
The cornerstone treatment for multifocal motor neuropathy (MMN), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (IVIg). The aim of this study is to identify prognostic factors of poor outcome. Data were retrospectively collected from MNN patients in three French centers. Patients were divided into two groups: a good outcome group and a poor outcome group. Demographic, clinical, biological and nerve conduction study features of MMN patients were analyzed. Identification of prognostic factors in MMN could help develop personalized treatment.

Detailed Description
-----------------
The cornerstone treatment for multifocal motor neuropathy (MMN), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (IVIg). However, 10% of patients progress despite treatment. The aim of this study is to identify prognostic factors of poor outcome. Data were retrospectively collected from MNN patients in three French centers. Patients were divided into two groups: a good outcome group (patients in remission without IVIg or with spaced IVIg courses), and a poor outcome group (patients dependent on continuous IVIg treatment or deteriorating despite IVIg). Investigators searched predictive factors of long-term outcome in MMN. They studied demographic, clinical, biological and nerve conduction study features of MMN patients.Identification of prognostic factors in MMN could help develop personalized treatment by selecting patients eligible for immunosuppressive drugs before IVIg dependence or progression.

Official Title
-----------------
Predictive Factors Identification of Long-term Outcome in Multifocal Motor Neuropathy (MMN) Treated With Intravenous Immunoglobulin (IVIG)

Conditions
-----------------
MMN

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of MNN following the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) Guideline criteria 2010 Exclusion Criteria: missing data clinical progression features suggested another inflammatory neuropathy, immunosuppressive agents for another pathology.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of deteriorating or strongly dependant IVIg NMM |  | inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
predictive factors
Influence of Vasculary Inflammation on Development of Diabetes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate if patients with coronary heart disease have higher risk to develop diabetes mellitus among the following two years. The examination of biomarkers taken from blood and fat issue shall provide which factors could be responsible for development of diabetes mellitus.

Official Title
-----------------
Influence of Vasculary Inflammation on Development of Diabetes

Conditions
-----------------
Coronary Artery Disease(CAD)

Intervention / Treatment
-----------------
* Procedure: biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients with MI signed informed consent older than 18 years ability to give informed consent Exclusion Criteria: absence of legal competence

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: biopsy of fat tissue<br> | Procedure: biopsy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fat tissue biopsy | Patients with Coronary artery disease(CAD) undergo a subcutane fat tissue biopsy to identify inflammation and diabetes biomarker, such as TNF, Adiponectin and Clock-Gene. This is done baseline, after 1 year and after 2 years. Comparison of the current measurements among the measurements of the following 2 years shall give evidence about the reasons and conditions of diabetes development. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood collection | Blood of patients with Coronary artery disease(CAD)is taken to identify biomarkers of inflammation and diabetes, such as CRP, HbA1c, Adiponectin, Plasma MMp-9, s-ICAM-1, s-VCAM-1, P-selectin and Clock-Gene, CD11b/CD18, CD14, L-selectin, CD-64 and TNF. This is done baseline, after 1 year and after 2 years. Comparison of the current measurements among the measurements of the following 2 years shall give an evidence about the reasons and conditions of diabetes development. | 2 years |
Effects of Long Term Calorie Restriction on Sphingomyelin and Amino Acids

Study Overview
=================
Brief Summary
-----------------
The effect of weight loss with long-term low calorie diet (LCD) on plasma metabolites is unknown. The aim was to examine whether a LCD-induced weight reduction results in changes in the extended plasma metabolites.

Detailed Description
-----------------
Overweight/obese subjects (25≤ BMI <33 kg/m2) aged 40 to 59 years consumed a LCD (an approximate 100 kcal/day calorie deficit) or a weight-maintenance diet (control) in a randomized, controlled design with 3-year intervention period.

Official Title
-----------------
Three-year Mild Calorie Restriction Partially Protects Against Age-related Increase in Sphingomyelin and Reduces Obesity-associated Amino Acids

Conditions
-----------------
Overweight, Obese

Intervention / Treatment
-----------------
* Dietary Supplement: LCD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 25 <= BMI < 33 kg/m2 Exclusion Criteria: type 2 diabetes cardiovascular disease psychiatric problems any medication use

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: control group<br>weight maintenance diet | |
| Experimental: low calorie diet (LCD) group<br>approximate 100 kcal/d calorie deficit | Dietary Supplement: LCD<br>* approximate 100 kcal/d caloric deficit<br>* Other names: weight loss diet;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anthropometry | weight, height, BMI, waist circumference, blood pressure | 3-year follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| biochemistry analysis | total-cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, free fatty acids, glucose, insulin, HOMA-IR, Lp-PLA2 | 3-year follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BMI, L-phenylalanine, low calorie diet, sphingomyelin, L-leucine
Zainidip in Renal Artery Stenosis

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy of renal artery stent combined with standardized medical therapy as treatment for renal artery stenosis.

Official Title
-----------------
The Efficacy of Renal Artery Stent Combined With Standardized Medical Therapy in Patients With Atherosclerotic Renal Artery Stenosis

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Device: stent
* Drug: Aspirine
* Drug: Clopidogrel
* Drug: Lercanidipine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 40 - 75 Diameter of stenosis of renal artery or main branch of renal artery ≥60％. If diameter of stenosis is 60% - 75%, pressure difference between proximal and distal end ≥20 mm Hg (1mmHg=0.133kPa) or Captopril renography positive; Systolic blood pressure before taking antihypertensive ≥180mmHg and/or diastolic blood pressure ≥110 mmHg; taking three antihypertensive including one diuretics with systolic blood pressure ≥140mmHg and/or ≥90 mmHg; length of ipsilateral kidney is greater than 7.0cm. Exclusion Criteria: Estimated glomerular filtration rate (eGFR) <30 ml/ (min﹒1.73 m 2) [eGFR (mL/min/1.73 m2) = 186.3 * serum creatinine (mg/dl) -1.154 * Age-0.203 * 0.742 (female)[11]; unstable condition and unable to tolerate interventional therapy; anatomy of renal artery pathology not suitable for interventional therapy; allergic to dihydropyridines; III degree atrioventricular block contrast allergy ; any known malignant tumor; non-compliant, history of alcoholism or drug abuse.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>patients receiving renal artery stenting and anti-hypertension drug for renal artery atherosclerosis | Device: stent<br>* patients receiving renal artery stenting for renal artery atherosclerosis<br>Drug: Aspirine<br>* 100mg Qd<br>Drug: Clopidogrel<br>* 75mg Qd<br>Drug: Lercanidipine<br>* 10-20mg Qd<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glomerular filtration rate |  | 12 months | 
| Blood pressure |  | 12 months |